Mark Saxon, DO
Psychiatry · Kingston, PANPI 1255389326
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $16,503 of the $21,490 with a category attached, or 76.8%. It is spread thinly across 39 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $6,995 and has fallen 57.4% since, to $2,983 in 2025. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,045 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Otsuka America Pharmaceutical, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Johnson & Johnson$2K
- plus $7K from 33 others
What the payments were for
- Speaking & faculty fees$4,64022%
- Food & beverage$16,50377%
- Education$3472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$2,600
- TRINTELLIX$2,040
- ARISTADA$470
- INGREZZA$247
- INVEGA SUSTENNA$244
- ARISTADA INITIO$118
How this compares
$21,490 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 61 | $387,427 |
| VraylarCariprazine Hcl | 72 | $124,803 |
| IngrezzaValbenazine Tosylate | 13 | $103,748 |
| Invega SustennaPaliperidone Palmitate | 26 | $94,602 |
| TrintellixVortioxetine Hydrobromide | 76 | $52,779 |
| RexultiBrexpiprazole | 20 | $39,550 |
| Bupropion XlBupropion Hcl | 787 | $16,861 |
| Aripiprazole | 445 | $14,383 |
| Vilazodone Hcl | 120 | $12,140 |
| BelsomraSuvorexant | 16 | $11,989 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 489 | $11,937 |
| SeroquelQuetiapine Fumarate | 25 | $11,897 |
| Lurasidone Hcl | 50 | $11,340 |
| Duloxetine Hcl | 393 | $7,470 |
| Sertraline Hcl | 574 | $6,806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,621 | $387,42761 claims |
| AbbVieVraylar | $4,531 | $124,80372 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,693 | $103,74813 claims |
| Johnson & JohnsonInvega Sustenna | $1,617 | $94,60226 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $3,320 | $52,77976 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,813 | $39,55020 claims |
| MerckBelsomra | $171 | $11,98916 claims |
| Almatica Pharma LLCSertraline Hcl | $68 | $6,806574 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Kingston
- Jane JesseKingston$617K
- Rebecca RomaPittsburgh$3.3M
- Robert NelsonWyomissing$2.2M
- Matthew BergerMoosic$1.7M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
- Michael ThasePhiladelphia$396K
- Michael KwiatBeaver$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.